Advanced Search
Current and Breaking News for Professionals, Consumers and Media



Click here to learn how to advertise on this site and for ad rates.

Alzheimer Issues Author: FDA Consumer Health Information Last Updated: Feb 7, 2013 - 11:07:43 AM



FDA Offers New Guidance on Developing Drugs for Alzheimer’s Disease

By FDA Consumer Health Information
Feb 7, 2013 - 11:03:23 AM



Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Ezine
For Email Marketing you can trust


Email this article
 Printer friendly page

(HealthNewsDigest.com) - Today, the U.S. Food and Drug Administration issued a proposal designed to assist companies developing new treatments for patients in the early stages of Alzheimer's disease, before the onset of noticeable (overt) dementia.(HealthNewsDigest.com) - Today, the U.S. Food and Drug Administration issued a proposal designed to assist companies developing new treatments for patients in the early stages of Alzheimer's disease, before the onset of noticeable (overt) dementia.


Alzheimer's disease is an irreversible, progressive brain disease that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks of daily living. In most people with Alzheimer's, symptoms first appear after age 60. Alzheimer's disease is the most common cause of dementia among older people.

"The scientific community and the FDA believe that it is critical to identify and study patients with very early Alzheimer's disease before there is too much irreversible injury to the brain," said Russell Katz, M.D., director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. "It is in this population that most researchers believe that new drugs have the best chance of providing meaningful benefit to patients."

The draft guidance titled, "Guidance for Industry, Alzheimer's Disease: Developing Drugs for the Treatment of Early Stage Disease," explains the FDA's current thinking about the way researchers can identify and select patients with early Alzheimer's disease, or those who are at risk of developing the disease, for participation in clinical trials. In recent years, the research community has tried to find ways to identify these patients using criteria that are based on biological indicators (biomarkers). Researchers have also tried to develop sensitive clinical measures that can detect subtle mental decline.

"This draft guidance is intended to serve as a focus for continued discussions between the FDA and pharmaceutical sponsors, the academic community, advocacy groups, and the public," adds Dr. Katz. "The FDA is committed to vigorously addressing Alzheimer's disease and will work with industry to help develop new treatments in this early population as expeditiously as possible."

For drugs designed to treat patients with overt dementia, the FDA currently requires that treatments not only show an effect on abnormal thinking, but also how well patients function. The goal for these trials is to ensure that any beneficial effect on thinking is associated with a clinically meaningful outcome for the patient, e.g., improvement or lack of decline in how patients feel or function.

However, because patients with early Alzheimer's disease have little-to-no impairment of global functioning, it is difficult to assess changes in function in these patients. This can make it difficult to determine if a given treatment's effect is clinically important.

The FDA is seeking public comment on the draft guidance for 60 days. Instructions on how to submit comments are included in a related Federal Register notice issued today. In finalizing the guidance document, the agency will consider the information received from the public.

The FDA proposal is part of U.S. Department of Health and Human Services' efforts under the National Plan to Address Alzheimer's Disease, which calls for both the government and the private sector to intensify efforts to treat or prevent Alzheimer's and related dementias and to improve care and services. It responds to recommendations from a May 2012 HHS and National Institutes of Health Alzheimer's research summit to conduct clinical trials in at-risk individuals without symptoms and to develop and validate new measures so that Alzheimer's can be measured at the earliest possible time in the course of the disease.

For more information:
--FDA Draft Guidance for Industry: Alzheimer's Disease: Developing Drugs for the Treatment of Early Stage of Disease  
--Federal Register Notice
--National Institute on Aging at NIH: Alzheimer's Disease Education and Referral Center
--alzheimers.gov ###
For advertising and promotion on www.HealthNewsDigest.com contact Mike McCurdy at: [email protected]  or call 877-634-9180. We are syndicated worldwide and read in 164 countries. We also have over 7,000 journalists as subscribers who may use our content for their own media!

###

For advertising and promotion on www.HealthNewsDigest.com contact Mike McCurdy at: [email protected]  or call 877-634-9180. We are syndicated worldwide and read in 164 countries. We also have over 7,000 journalists as subscribers who may use our content for their own media!



Top of Page

HealthNewsDigest.com

Alzheimer Issues
Latest Headlines


+ Alzheimer’s Replicated in Petri Dish for First Time
+ 5 Things You Can Do to Prevent Alzheimer’s Disease
+ Drug for People with Mild-to-moderate Alzheimer’s Disease
+ Watch For Warning Signs Of Alzheimer’s During The Holidays
+ A Potential Blood Test for Alzheimer’s
+ New Hope for Treatment of Alzheimer's Disease
+ Knowing the Difference Between Alzheimer’s and Dementia
+ Alzheimer's Association Applauds Inclusion of Additional $100 Million for Alzheimer's Disease in Senate Funding Bill
+ Alzheimer’s: Gene Variant Puts Women at Higher Risk
+ Medication to Treat Agitation for Alzheimer Disease Shows Mixed Results



Contact Us | Job Listings | Help | Site Map | About Us
Advertising Information | HND Press Release | Submit Information | Disclaimer

Site hosted by Sanchez Productions